Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Cytokine ; 15(6): 315-9, 2001 Sep 21.
Artículo en Inglés | MEDLINE | ID: mdl-11594798

RESUMEN

Hepatocyte growth factor (HGF) is a secreted cytokine which is expressed in the central nervous system (CNS) together with its specific receptor MET. Since HGF exerts strong neurotrophic activity including motoneurons, we have further analysed whether the HGF/MET axis is defective in patients with amyotrophic lateral sclerosis (ALS). Intrathecal HGF-secretion was measured in cerebrospinal fluid (CSF) from patients with amyotrophic lateral sclerosis and in controls without neurological diseases using a specific sandwich immunoassay (ELISA). MET-expression was analysed by immunohistology in spinal cord cross-sections of ALS patients and unaffected controls. The HGF concentrations in CSF were moderately but significantly increased in ALS patients compared to healthy controls (580 pg/ml vs 348 pg/ml). MET-protein was detectable in spinal cord motoneurons of patients with ALS as well as unaffected controls. The data demonstrate that ALS does not show a lack of the trophic signalling axis, HGF/MET, suggesting that the signalling system itself is not affected. The moderate increase in HGF-secretion may represent a compensatory effect.


Asunto(s)
Esclerosis Amiotrófica Lateral/líquido cefalorraquídeo , Esclerosis Amiotrófica Lateral/metabolismo , Factor de Crecimiento de Hepatocito/líquido cefalorraquídeo , Factor de Crecimiento de Hepatocito/metabolismo , Adulto , Anciano , Estudios de Casos y Controles , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Neuronas/metabolismo , Transducción de Señal , Médula Espinal/metabolismo
2.
Acta Neurol Scand ; 103(1): 2-6, 2001 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11153883

RESUMEN

OBJECTIVES: To evaluate if increased metabolic demand in remaining motor neurons in ALS spinal cord sections can be visualized by 3H-vesamicol binding. MATERIAL AND METHODS: As a presumed marker of the vesicular acetylcholine transporter, 3H-vesamicol was applied in quantitative autoradiography in cervical spinal cord sections from 11 ALS patients and 4 control cases. The regional binding was compared to that of the muscarinic ligand 3H-QNB. RESULTS: Our results demonstrate the same magnitude of H-vesamicol binding in the ventral horn of ALS spinal cord as compared to controls, despite the profound loss of motor neurons in that specific area in ALS. The specificity of 3H-vesamicol binding for the cholinergic transporter is high in the motor neuron area, and sigma-sites constitute a minor proportion. CONCLUSION: The lack of decrease in 3H-vesamicol binding in postmortem ALS spinal cord sections probably reflects an upregulated synthesis of vesicular membranes in remaining and hyperactive motor neurons in vivo.


Asunto(s)
Proteínas Portadoras/metabolismo , Metabolismo Energético/fisiología , Proteínas de Transporte de Membrana , Enfermedad de la Neurona Motora/patología , Neuronas Motoras/patología , Fármacos Neuromusculares Despolarizantes/farmacocinética , Piperidinas/farmacocinética , Proteínas de Transporte Vesicular , Autorradiografía , Humanos , Valores de Referencia , Médula Espinal/patología , Tritio , Proteínas de Transporte Vesicular de Acetilcolina
3.
Neuroreport ; 11(8): 1781-3, 2000 Jun 05.
Artículo en Inglés | MEDLINE | ID: mdl-10852244

RESUMEN

Cerebrospinal fluid from 15 patients with ALS and 11 controls without neurological disease were analysed for levels of the neurotrophic factors BDNF and GDNF. Analyses were performed using a sensitive sandwich immunoassay (ELISA). There was no significant difference in BDNF levels between the ALS patients and the control subjects studied. Measurable levels of GDNF were found in 12 out of 15 ALS samples. GDNF was not detected in CSF from any of the control subjects. The finding of increased CSF levels of GDNF in ALS compared to controls, together with earlier findings of increased expression of GDNF mRNA in muscle in ALS, indicates that the capacity to synthesize GDNF is enhanced in this disorder.


Asunto(s)
Esclerosis Amiotrófica Lateral/líquido cefalorraquídeo , Factor Neurotrófico Derivado del Encéfalo/líquido cefalorraquídeo , Factores de Crecimiento Nervioso , Proteínas del Tejido Nervioso/líquido cefalorraquídeo , Adulto , Anciano , Esclerosis Amiotrófica Lateral/tratamiento farmacológico , Femenino , Factor Neurotrófico Derivado de la Línea Celular Glial , Humanos , Masculino , Persona de Mediana Edad , Fármacos Neuroprotectores/uso terapéutico , Valores de Referencia , Riluzol/uso terapéutico
4.
Acta Neurol Scand ; 100(5): 317-21, 1999 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-10536919

RESUMEN

OBJECTIVES: To investigate if degeneration of motor neurons in amyotrophic lateral sclerosis (ALS) is related to altered levels of the apoptosis regulating proteins Bcl-2 and Bax. In addition, immunoreactivity of the cysteine protease ICH-IL and detection of motor neurons with DNA fragmentation, indicative of apoptosis, was also studied. MATERIAL AND METHODS: The immunoreactivity of Bcl-2, Bax and ICH-1L were compared in ALS and control spinal cord motor neurons by immunohistochemical analysis and motor neurons with DNA fragmentation were identified by the TUNEL-method. RESULTS: The results demonstrate an increased expression of Bax in the ALS material as compared to controls but no change in Bcl-2 and ICH-1L expressions. Moreover, a larger proportion of motor neurons stained positive for TUNEL in ALS spinal cords. CONCLUSION: Present study suggest an upregulation of the cell death promoting protein Bax and increased DNA degradation, indicative of apoptosis, in spinal motor neurons of ALS patients.


Asunto(s)
Esclerosis Amiotrófica Lateral/genética , ADN/metabolismo , Neuronas Motoras/patología , Proteínas Proto-Oncogénicas c-bcl-2 , Proteínas Proto-Oncogénicas/genética , Nervios Espinales/patología , Anciano , Esclerosis Amiotrófica Lateral/fisiopatología , Apoptosis/genética , Femenino , Genes bcl-2/genética , Humanos , Masculino , Persona de Mediana Edad , Regulación hacia Arriba , Proteína X Asociada a bcl-2
5.
J Neurol Sci ; 162(2): 169-73, 1999 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-10202982

RESUMEN

The expression of glial cell line-derived neurotrophic factor (GDNF) mRNA and brain-derived neurotrophic factor (BDNF) mRNA were studied in muscle biopsies from five patients with amyotrophic lateral sclerosis (ALS), six patients with other neuromuscular diseases and eight healthy control persons. All five patients with ALS had higher GDNF mRNA expressions in their biopsies than the healthy control group (almost a three fold increase). Among the other patients only one, who had a rapidly progressing toxic polyneuropathy, showed a GDNF mRNA expression above those of the controls. The BDNF mRNA expressions in the biopsies from the ALS patients were in the same range as those from the healthy controls, although the mean value of the ALS patients was higher. The only biopsy that showed a markedly higher BDNF mRNA expression was taken from one patient with progressive muscular atrophy. These results suggest that increased GDNF mRNA expression in muscle is an unspecific response to ongoing denervation and that this response is maintained in ALS, at least temporarily. If increased GDNF mRNA in muscle proves to be a constant finding in ALS the rationale for the use of GDNF as a therapeutic agent in ALS must be questioned.


Asunto(s)
Esclerosis Amiotrófica Lateral/metabolismo , Músculo Esquelético/metabolismo , Factores de Crecimiento Nervioso/genética , Proteínas del Tejido Nervioso/genética , ARN Mensajero/biosíntesis , Adulto , Anciano , Esclerosis Amiotrófica Lateral/patología , Biopsia , Estudios de Casos y Controles , Femenino , Factor Neurotrófico Derivado de la Línea Celular Glial , Humanos , Masculino , Persona de Mediana Edad , Músculo Esquelético/patología
6.
Int J Neural Syst ; 7(2): 129-47, 1996 May.
Artículo en Inglés | MEDLINE | ID: mdl-8823624

RESUMEN

In the construction of neural networks involving associative recall, information is sometimes best encoded with a local representation. Moreover, a priori knowledge can lead to a natural selection of connection weights for these networks. With predetermined and fixed weights, standard learning algorithms that work by altering connection strengths are unable to train such networks. To address this problem, this paper derives a supervised learning rule based on gradient descent, where connection weights are fixed and a network is trained by changing the activation rule. It incorporates both traditional and competitive activation mechanisms, the latter being an efficient method for instilling competition in a network. The learning rule has been implemented, and the results from several test networks demonstrate that it works effectively.


Asunto(s)
Algoritmos , Inteligencia Artificial , Redes Neurales de la Computación , Cognición , Simulación por Computador , Modelos Psicológicos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA